The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

Medications like Ozempic, Wegovy, and Zepbound have helped many Americans lose weight, but there are still some misconceptions about these medications and metabolic health. Centre Spring MD founder ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain following bariatric surgery, a Swiss real-world study reveals.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat.

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

Consumers may cycle on and off GLP-1 medications because of financial constraints. These consumers present opportunities for ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...